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INTRODUCTION
Pulmonary alveolar microlithiasis (PAM) is a rare 
idiopathic lung disease, characterized by the formation and 
accumulation of tiny, round corpuscles called “microliths” 
that consist primarily of calcium and phosphorus mixed 
with small amounts of magnesium and aluminum1. Most of 
the reported cases are of patients between 20 and 40 years 
of age. Autosomal recessive inheritance has been suggested 
to be a possible cause of the disease. Clinical features vary, 
and some patients may be asymptomatic for a long time 
until pulmonary function testing begins to demonstrate 
lung impairment along with progressive fibrosis and the 
development of a restrictive ventilatory defect culminating 
in cardiorespiratory decompensation.2 Currently, there is 
no medical therapy capable of definitively changing the 
progression of the disease. Lung transplantation is required 
once end-stage lung disease is established. To date, seven 
patients have received lung transplantation for this condition. 
We report a successful case of bilateral sequential lung 
transplantation in a patient with PAM.
CASE DESCRIPTION
A 47-year-old man was referred for lung transplantation 
due to shortness of breath. He reported dyspnea that began 
two years prior to his presentation in our clinic, with 
progressive worsening that eventually required oxygen. 
There was no history of smoking or previous pulmonary 
disease, except for a history of tuberculosis 30 years 
prior, for which he had received treatment. On physical 
examination, there was marked digital clubbing, mild 
cyanosis, cor pulmonale and bilateral prominent inspiratory 
crackles. Chest X-ray showed bilateral pleural thickening, 
elevation of the hilum and diffuse interstitial opacity. A 
computed tomography (CT) scan demonstrated thickening 
of the interlobular septa and interstitia, lymph node 
enlargement, pleural thickening with calcification, ground 
glass opacity and areas of honeycombing due to multiples 
nodules diffusely distributed over the parenchyma (Figure 
1). An echocardiogram showed pulmonary hypertension, 
left ventricular diastolic dysfunction and right systolic 
dysfunction. Open lung biopsy revealed PAM. Prednisone 
treatment was initiated, with partial improvement as a result. 
There was no family history of similar disease. He showed 
a restrictive ventilatory defect on pulmonary function test, 
with a Forced Expiratory Volume in 1 second (FEV1) of 
1.63 L (46% of the predicted value), a Forced Vital Capacity 
(FVC) of 1.84 L (43% of predicted) and an FEV1/FVC ratio 
of 0.89 (108% of predicted).
The patient underwent bilateral lung transplantation 
after fourteen months on the waiting list. The procedure 
was performed by clamshell incision. The left lung was 
transplanted first, and cardiopulmonary bypass was 
necessary for 135 minutes due to hemodynamic instability. 
The right lung was transplanted without cardiopulmonary 
bypass. Total ischemic time was 540 minutes.
Histological examination showed PAM with foci of 
metaplastic ossification, extensive cicatricial fibrosis, 
primarily in the peripheral areas, and paraseptal emphysema 
in the apical portion of the upper lobes with formation of 
subpleural bubbles (Figure 2). In the early postoperative 234
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period, the patient presented with pulmonary reperfusion 
syndrome, distributive shock and acute renal failure, requiring 
dialysis for 26 days. Total mechanic ventilation time was 6 
days, and ICU stay was 38 days. Immunosuppressive therapy 
was initiated with tacrolimus, sodium mycophenolate and 
prednisone. The patient progressed uneventfully with total 
recovery of renal function and remained well twelve months 
after transplantation, as may be observed from his current 
pulmonary function testing results: FEV1 of 2.61 L (75% of 
predicted), FVC of 3.43 L (81% of predicted) and FEV1/FVC 
ratio of 0.76 (92.2% of predicted).
DISCUSSION
Although the first cases of PAM were described by 
Malphighi, the disease was first named by Phur.3 The 
disease exists on all continents, without regional or ethnic 
differences, although most of the cases (37%) have been 
reported in Europe and Asia Minor. Turkey is the country 
with the highest prevalence (16.3%), followed by Italy and 
the USA. The etiology of the condition remains unknown, 
although some theories have been posited. One theory is 
based on an exudate that is not easily absorbed and that is 
formed as a result of an abnormal inflammatory response to 
infections or irritants, ultimately undergoing calcification. 
It is also postulated that a condensation of alveolar mucus 
due to a deficiency in mucociliary clearance is the cause 
of the disease. However, the most accepted hypothesis is 
that mucopolysaccharide deposition, triggered by increased 
alkalinity secondary to inborn errors in metabolism involving 
the carbonic anhydrase enzyme at the alveolar interface, 
promotes the local accumulation of calcium salts.4,5
Diagnosis is usually made between the second and 
third decade of life; however, the age group can be highly 
variable. The disease has been reported in neonates and 
octogenarians. In the present case, diagnosis occurred at 
the age of 45. The condition is sometimes misdiagnosed 
as miliary tuberculosis. Family history is present in 37% to 
56% of the cases. In cases where there is a family history, 
a higher incidence in females has been described (53.3%). 
Otherwise, in sporadic cases, the predominance is higher in 
males (61.3%).2,3
The typical picture of PAM on chest X-ray is of fine, 
sand-like calcific micronodules (sandstorm lung) diffusely 
infiltrating both lungs; these characteristics are usually 
observed in the middle and lower zones.6 The protrusion of 
microliths under the visceral pleura may cause the granular 
aspect often present on the external surface of the lungs. 
On the anterior margin and at the apex, areas of bullous 
emphysema may also be found. CT scans demonstrate 
Figure 1 - CT scan showing pleural thickening with calcification and multiples nodules diffusely distributed over the lung parenchyma.  
Figure 2 - Macroscopic view of the explanted lung showing a more consis-
tent pulmonary parenchyma with reduced aeration, making the tissue more 
difficult to be sectioned. The surface of the piece exhibits a granular aspect. 
A “sandy” material is obtained by its manipulation.235
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micronodular calcific densities with a greater concentration 
in the subpleural parenchyma and along the bronchovascular 
bundles, whereas high resolution CT scans show thickening 
of the lobular septae with a distribution of microliths along 
the septae and around the centrilobular distal bronchioles.
On gross examination, apical blebs and bullae may 
be present, and the lungs appear to remain inflated and 
are described as heavy with gritty texture (Figure 2). 
Concentrically laminated concretions (1 to 3 mm in 
diameter) may be found inside the alveoli, which are often 
considered normal, although diffuse interstitial fibrosis may 
be observed in more severe cases (Figure 3).
At present, there is no medical treatment capable 
of reducing the progression of the disease. Systemic 
corticosteroids, calcium-chelating agents and serial 
bronchopulmonary  lavage  have  been  shown  to  be 
ineffective and are used as palliative treatments. The use 
of diphosphonate has been proposed to reduce calcium 
phosphate precipitation in pulmonary alveoli.7 However, this 
therapy remains controversial given the limited number of 
reports in the literature. 
Lung transplantation remains the only possible treatment 
for end-stage cases8. Nonetheless, decisions regarding the 
time at which transplantation should occur are not fully 
established due to the lack of well-defined prognostic 
indices and the insidious nature of PAM9. When either right 
heart failure or severe respiratory failure with a requirement 
for oxygen is present, as was the case in our study, 
transplantation should be considered. In order to maximize 
the chances of a successful outcome, patients should be 
referred before the development of severe right ventricular 
dysfunction. In the only postoperative death reported after 
bilateral lung transplantation, prolonged cardiopulmonary 
bypass (six hours) in combination with extensive pleural 
involvement and increased vascularity led to uncontrolled 
hemorrhagic complications. Shigemura et al. have reported 
the oldest successful lung transplant recipient, with ten years 
of follow-up.10
Bilateral lung replacement is preferred to unilateral 
replacement, because the replacement of only one lung 
might result in persistent shunting of blood through the 
native lung, as PAM leads to filling of the alveolar spaces 
and the consequent creation of large areas of intrapulmonary 
shunt.11 However, two patients have undergone a single 
lung transplantation with acceptable results and have had 
no evidence of recurrence in the transplanted lung thus 
far.12,13 Furthermore, even for bilateral transplantation, it 
is not known whether PAM can recur. Recurrence after 
transplantation has not been reported to date, suggesting that, 
in fact, PAM is a result of local inflammatory responses or a 
genetically determined error in alveolar metabolism, rather 
than a systemic disorder. Increased right ventricular ejection 
fraction and the regression of right ventricular hypertrophy 
are examples of heart function recovery after bilateral lung 
transplantation, which is an effective treatment option for 
end-stage PAM patients, despite the reduced number of 
reported cases worldwide.
Figure 3 - Hystologic specimen from the explanted lung demonstrat-
ing the pulmonary histological structure diffusely altered due to alveoli 
filled by multiples microliths. The interstitial septa is enlarged by fibrosis 
(hematoxylin-eosin 40X).
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